Peter M Wolfgram1, Aaron L Carrel, David B Allen. 1. Department of Pediatrics, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin 53792-4108, USA.
Abstract
PURPOSE OF REVIEW: Recombinant human growth hormone (hGH) therapy in children with Prader-Willi syndrome (PWS) improves linear growth, body composition, physical strength and agility, and other metabolic parameters. These benefits must be weighed against potential adverse effects, including rare occurrences of sudden death. This review summarizes recent evidence important to a benefit-risk analysis of hGH use in children with PWS. RECENT FINDINGS: Studies consistently show that hGH improves stature, body composition, fat percentage and distribution, and other metabolic markers in children with PWS. Preliminary reports of improved cognitive development during hGH have also emerged. Scoliosis progression is influenced by growth rate, but frequency of occurrence and severity are not increased by hGH exposure. PWS genotype does not appear to affect response to hGH. Concerns about hGH-associated sudden death persist, but recent studies show either absence of change in sleep-disordered breathing or improved sleep cardiovascular function during hGH therapy. SUMMARY: Recent studies confirm and expand reported benefits of hGH therapy in children with PWS, including a possible salutary role in cognitive development. These findings support previous assertions that hGH can reduce morbidity and improve function in children with PWS, and suggest that potential risks of such treatment are favorably balanced by its benefits.
PURPOSE OF REVIEW: Recombinant humangrowth hormone (hGH) therapy in children with Prader-Willi syndrome (PWS) improves linear growth, body composition, physical strength and agility, and other metabolic parameters. These benefits must be weighed against potential adverse effects, including rare occurrences of sudden death. This review summarizes recent evidence important to a benefit-risk analysis of hGH use in children with PWS. RECENT FINDINGS: Studies consistently show that hGH improves stature, body composition, fat percentage and distribution, and other metabolic markers in children with PWS. Preliminary reports of improved cognitive development during hGH have also emerged. Scoliosis progression is influenced by growth rate, but frequency of occurrence and severity are not increased by hGH exposure. PWS genotype does not appear to affect response to hGH. Concerns about hGH-associated sudden death persist, but recent studies show either absence of change in sleep-disordered breathing or improved sleep cardiovascular function during hGH therapy. SUMMARY: Recent studies confirm and expand reported benefits of hGH therapy in children with PWS, including a possible salutary role in cognitive development. These findings support previous assertions that hGH can reduce morbidity and improve function in children with PWS, and suggest that potential risks of such treatment are favorably balanced by its benefits.
Authors: A A van der Klaauw; J A Romijn; N R Biermasz; J W A Smit; J van Doorn; O M Dekkers; F Roelfsema; A M Pereira Journal: Eur J Endocrinol Date: 2006-11 Impact factor: 6.664
Authors: U Eiholzer; R Gisin; C Weinmann; S Kriemler; H Steinert; T Torresani; M Zachmann; A Prader Journal: Eur J Pediatr Date: 1998-05 Impact factor: 3.183
Authors: D A M Festen; M Wevers; A C Lindgren; B Böhm; B J Otten; J M Wit; H J Duivenvoorden; A C S Hokken-Koelega Journal: Clin Endocrinol (Oxf) Date: 2007-11-19 Impact factor: 3.478
Authors: Moris A Angulo; Mariano Castro-Magana; Michele Lamerson; Raul Arguello; Siham Accacha; Asjad Khan Journal: Am J Med Genet A Date: 2007-07-01 Impact factor: 2.802
Authors: Aaron L Carrel; Susan E Myers; Barbara Y Whitman; Jens Eickhoff; David B Allen Journal: J Clin Endocrinol Metab Date: 2010-01-08 Impact factor: 5.958
Authors: Dai Yang-Li; Luo Fei-Hong; Zhang Hui-Wen; Ma Ming-Sheng; Luo Xiao-Ping; Liu Li; Wang Yi; Zhou Qing; Jiang Yong-Hui; Zou Chao-Chun Journal: Orphanet J Rare Dis Date: 2022-06-13 Impact factor: 4.303
Authors: Dennis M Styne; Silva A Arslanian; Ellen L Connor; Ismaa Sadaf Farooqi; M Hassan Murad; Janet H Silverstein; Jack A Yanovski Journal: J Clin Endocrinol Metab Date: 2017-03-01 Impact factor: 5.958